The Postoperative Ileus drugs in development market research report provides comprehensive information on the therapeutics under development for Postoperative Ileus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Postoperative Ileus. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Postoperative Ileus - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Postoperative Ileus and features dormant and discontinued products.

GlobalData tracks five drugs in development for Postoperative Ileus by five companies/universities/institutes. The top development phase for Postoperative Ileus is phase i with two drugs in that stage. The Postoperative Ileus pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Postoperative Ileus pipeline products market are: RaQualia Pharma, Palisade Bio and Shionogi.

The key targets in the Postoperative Ileus pipeline products market include Serine Endopeptidase (Serine Protease or EC 3.4.21.), Mu Type Opioid Receptor (MOR1 or Mu Opiate Receptor or Mu Opioid Receptor or OPRM1), and Motilin Receptor (G Protein Coupled Receptor 38 or GPR38 or MLNR).

The key mechanisms of action in the Postoperative Ileus pipeline product include Motilin Receptor (G Protein Coupled Receptor 38 or GPR38 or MLNR) Agonist with one drug in Preclinical. The Postoperative Ileus pipeline products include two routes of administration with the top ROA being Oral and one key molecule types in the Postoperative Ileus pipeline products market including Small Molecule.

Postoperative Ileus overview

Postoperative ileus is a prolonged absence of bowel function after surgical procedures, usually abdominal surgery. It is caused by interruption of the GI tract, bowel manipulation, anesthetics and analgesics, immobility, electrolyte imbalances, intra-abdominal hematoma, severe infections or sepsis, and chronic medical conditions like diabetes. Symptoms of ileus include bloating, vomiting, constipation, cramps, and loss of appetite. Some drugs used to treat postoperative ileus include metoclopramide, cisapride, and erythromycin.

For a complete picture of Postoperative Ileus’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.